PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - van Vollenhoven, Ronald
TI  - Etanercept Proves Clinically Superior to Discontinuation: Results from the DOSERA Trial
DP  - 2012  01
TA  - MD Conference Express
PG  - 16--17
VI  - 12
IP  - 19
4099  - http://mdc.sagepub.com/content/12/19/16.short
4100  - http://mdc.sagepub.com/content/12/19/16.full
AB  - This article discusses results from the late-breaking Study Comparing the Effect on Disease Activity When Reducing or Discontinuing Etanercept in Subjects with RA [DOSERA; NCT00858780]. The results showed that in patients with rheumatoid arthritis and stable low disease activity on methotrexate plus etanercept, continued treatment with etanercept at 25 or 50 mg/week provides a significantly higher likelihood of maintaining a stable disease state over 48 weeks than placebo.